It’s been a pretty great week for Opus Genetics, Inc. (NASDAQ:IRD) shareholders, with its shares surging 12% to US$1.20 in the week since its latest second-quarter results. Revenues came in at US$2.9m, a whole 32% below what the analysts were forecasting. Losses were a (relative) bright spot by comparison, with a per-share (statutory) loss of US$0.12 substantially smaller than what was expected. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. Readers will be glad to know we’ve aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Opus Genetics after the latest results.
NasdaqCM:IRD Earnings and Revenue Growth August 16th 2025
Taking into account the latest results, the current consensus, from the four analysts covering Opus Genetics, is for revenues of US$14.3m in 2025. This implies a measurable 7.4% reduction in Opus Genetics’ revenue over the past 12 months. Losses are predicted to fall substantially, shrinking 50% to US$0.49. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$17.3m and losses of US$0.84 per share in 2025. So there’s been quite a change-up of views after the recent consensus updates, withthe analysts making a serious cut to their revenue forecasts while also reducing the estimated losses the business will incur.
See our latest analysis for Opus Genetics
The analysts have cut their price target 11% to US$6.00per share, suggesting that the declining revenue was a more crucial indicator than the forecast reduction in losses. The consensus price target is just an average of individual analyst targets, so – it could be handy to see how wide the range of underlying estimates is. Currently, the most bullish analyst values Opus Genetics at US$8.00 per share, while the most bearish prices it at US$5.00. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await Opus Genetics shareholders.
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We would highlight that revenue is expected to reverse, with a forecast 14% annualised decline to the end of 2025. That is a notable change from historical growth of 37% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 20% annually for the foreseeable future. It’s pretty clear that Opus Genetics’ revenues are expected to perform substantially worse than the wider industry.
Story Continues
The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Unfortunately, they also downgraded their revenue estimates, and our data indicates underperformance compared to the wider industry. Even so, earnings per share are more important to the intrinsic value of the business. Still, earnings are more important to the intrinsic value of the business. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of Opus Genetics’ future valuation.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have forecasts for Opus Genetics going out to 2027, and you can see them free on our platform here.
Plus, you should also learn about the 4 warning signs we’ve spotted with Opus Genetics (including 2 which make us uncomfortable) .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.